Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Affiliations

• ¹ Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
• ² Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
• ³ Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA.
• ⁴ Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
• ⁵ Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
• ⁶ Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
• ⁷ Département de Médecine, Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada.
• ⁸ Maisonneuve-Rosemont Hospital Research Centre, Montréal, QC, Canada.
• ⁹ Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
• ¹⁰ Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
• ¹¹ Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA. jan@revmed.com.
• ¹² Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA. rosenn@mskcc.org.